Design In the obesity trial, 338 participants (mean age 48 years, 48% women, mean BMI 37.3 kg/m 2 ) were randomised (2:1:1:1:1:2:2) to retatrutide 1 mg, 4 mg (titration), 4 mg (no titration), 8 mg (slow titration), 8 mg (fast titration), 12 mg or placebo over 48 weeks [45]
The pattern is that both are GI-forward drugs, but retatrutides glucagon activity adds a cardiovascular consideration (heart rate) that cagrilintides amylin mechanism does not, and the same potency that produces retatrutides larger weight loss is associated, in indirect analyses, with a heavier adverse-event load
The choice between semaglutide and tirzepatide often comes down to effectiveness goals versus cost considerations
Cardiovascular Safety: Long-Term Heart Health GLP-1 receptor agonists have demonstrated cardiovascular benefits in long-term trials
It is important to note that venous samples are required for measuring glucose concentration since conditions such as Raynauds disease and relative hypotension might cause capillary blood glucose to be falsely low [50]
The jump from 15% to 25% weight loss transforms the clinical significance of the treatment
